Tirzepatide cleared for use, intensifying competition with Novo Nordisk in the biggest Asian market
21 May 2024 - 15:54
byAndrew Silver
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
A box of Eli Lilly's tirzepatide injection drug.. Picture: REUTERS/GEORGE FREY
Shanghai — Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market.
Novo Nordisk’s popular diabetes drug Ozempic won approval from China in 2021 and the company saw sales of the weekly injection in the greater China region that includes Hong Kong and Taiwan double to 4.8-billion kroner ($698m) last year.
Eli Lilly did not say when sales would begin in China or how many doses would be supplied.
Tirzepatide is the active ingredient in the US firm’s diabetes drug Mounjaro and weight-loss drug Zepbound.
Eli Lilly and Novo Nordisk are racing to increase production in a weight-loss market estimated to reach at least $100bn globally by decade’s end. Both companies’ obesity treatments belong to a class of drugs originally developed for diabetes known as GLP-1 agonists.
GLP-1 drugs have been shown to help patients lose on average as much as 20% of their weight, fuelling unparalleled demand.
Novo Nordisk expected in March that its weight-loss drug Wegovy would be approved for sale in China this year and launched with limited supply in the country, which experts estimate has the world’s highest number of people who are overweight or obese
Skyrocketing demand for Zepbound drove Eli Lilly to raise its annual sales forecast by $2bn last month.
The US Food and Drug Administration said last month that most doses of Mounjaro and Zepbound would be in limited supply through the second quarter of this year due to increased demand.
Mounjaro has been approved in the US since 2022 for patients with type 2 diabetes to control their blood sugar levels. It was approved in the US for weight loss under the brand name Zepbound late last year.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
China approves Eli Lilly diabetes drug
Tirzepatide cleared for use, intensifying competition with Novo Nordisk in the biggest Asian market
Shanghai — Eli Lilly said on Tuesday its diabetes drug tirzepatide has received approval from Chinese regulators, setting up intensifying competition with its Danish rival Novo Nordisk in the key Asian market.
Novo Nordisk’s popular diabetes drug Ozempic won approval from China in 2021 and the company saw sales of the weekly injection in the greater China region that includes Hong Kong and Taiwan double to 4.8-billion kroner ($698m) last year.
Eli Lilly did not say when sales would begin in China or how many doses would be supplied.
Tirzepatide is the active ingredient in the US firm’s diabetes drug Mounjaro and weight-loss drug Zepbound.
Eli Lilly and Novo Nordisk are racing to increase production in a weight-loss market estimated to reach at least $100bn globally by decade’s end. Both companies’ obesity treatments belong to a class of drugs originally developed for diabetes known as GLP-1 agonists.
GLP-1 drugs have been shown to help patients lose on average as much as 20% of their weight, fuelling unparalleled demand.
Novo Nordisk expected in March that its weight-loss drug Wegovy would be approved for sale in China this year and launched with limited supply in the country, which experts estimate has the world’s highest number of people who are overweight or obese
Skyrocketing demand for Zepbound drove Eli Lilly to raise its annual sales forecast by $2bn last month.
The US Food and Drug Administration said last month that most doses of Mounjaro and Zepbound would be in limited supply through the second quarter of this year due to increased demand.
Mounjaro has been approved in the US since 2022 for patients with type 2 diabetes to control their blood sugar levels. It was approved in the US for weight loss under the brand name Zepbound late last year.
Reuters
Hundreds of websites found selling fake weight-loss drugs
Eli Lilly signs deal with Amazon to deliver medicines
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Related Articles
Roche shares gain on weight loss drug results in trial
Runaway obesity drug demand drives Novo Nordisk profit boost
Novo aims to seek German insurance coverage of Wegovy heart use
WeightWatchers shares plunge as Oprah exits board
Weight-loss drugs fatten Eli Lilly and Novo Nordisk
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.